In 2023, the Monoclonal Antibodies Market was valued at $254.38 Billion and is projected to reach a market size of $534.9 Billion by 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 11.2%.
Monoclonal antibody (mAb) therapy is an immunotherapy that involves the use of monoclonal antibodies to attach to specific cells or proteins. Monoclonal antibodies are identical immune cell clones of a single mother cell. They can bind to a specific antigen when given as these antibodies have a monovalent affinity. Monoclonal antibodies are useful tools for detecting and purifying chemicals owing to their site-specificity and they have a wide range of applications in molecular biology, biochemistry, and medicine. Monoclonal antibodies are used to boost or decrease the immune response in a variety of medical situations and to treat diseases like cancer, heart disease, and stroke. Anti-cancer monoclonal antibodies, which reduce cell proliferation and prevent metastasis, neuropharmacological monoclonal antibodies, immunological monoclonal antibodies, anti-infective monoclonal antibodies, and other MAbs for humans and animals are all part of this industry.
Increased prevalence of cancer and chronic diseases, high demand for biologics, increased demand for cost-effective biosimilar monoclonal antibodies, and increased genomics R&D activities, as well as the introduction of technologically advanced genetic platforms, such as next-generation sequencing, are the major factors driving the market growth. Furthermore, an increase in patient and physician awareness of the applications of monoclonal antibodies (mAb) therapy, an increase in research collaborations for the development of a robust drug pipeline, and the approval of mAbs for various applications all contribute to the market's growth.
MARKET DRIVERS:
Monoclonal antibodies market growth potential is boosted by a strong focus on the research and development of novel monoclonal antibody therapeutics to provide highly targeted treatment for complex and severe diseases. Growing government support and regulatory approvals are contributing to the monoclonal antibodies market growth. For instance, the European Commission (EC) authorized Bristol Myers Squibb's OPDIVO and Yervoy combination therapy to treat patients with malignant pleural mesothelioma in June 2021. As a result, the product line's availability in the market will be extended.
Growing applications of monoclonal antibodies and high adoption of mAb therapies in oncology are contributing to the market growth
Monoclonal antibodies have numerous applications, allowing a single mAb to target multiple cancer types. As a result, rising cancer rates are likely to increase product demand in the future. The monoclonal antibodies market is growing owing to the increasing availability of cost-effective biosimilar monoclonal antibodies. The goal of biosimilars is to reduce the cost of medication and enhance access to treatment by addressing rising healthcare costs and dealing with economic pressure from patients and governments. Furthermore, to meet the rising disease burden, prominent market players are engaging in research and development efforts to provide the segment with unparalleled growth potential in the future.
MARKET RESTRAINTS:
The strict regulatory framework for the approval process is likely to hamper the market growth
Despite the positive results of monoclonal antibodies in the treatment of a variety of diseases, the lengthy and demanding requirements for approval and launch of monoclonal antibodies therapy can be a substantial roadblock to market revenue. Many clinical studies fall short of meeting the regulatory bodies' strict requirements and end outcomes. Other issues limiting the monoclonal antibody therapy market's growth include the medications' potential negative effects.
The high manufacturing cost of some monoclonal antibody therapeutics can be a challenge in the market growth
Therapeutic monoclonal antibodies (mAbs) are among the most expensive medications on the market. The current method of producing therapeutic mAbs necessitates the use of very large mammalian cell cultures followed by significant purification steps under GMP conditions, resulting in extremely expensive manufacturing costs. The high cost of mAbs has hampered their development as medicines. Certain novel technologies, such as plant-based mAb manufacturing, may minimize the cost. Plants can be utilized as bioreactors to produce therapeutic antibodies in big quantities at a low cost.
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
11.2% |
|
Segments Covered |
By Source, Indication, End User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
AbbVie Inc., Bristol Myers Squibb, Amgen, F. Hoffmann-La Roche, Bristol Myers Squibb, Merck & Co., Inc., Regeneron Pharmaceuticals Inc., AstraZeneca, Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG among others |
Segmentation Analysis
Based on the Source, the Monoclonal Antibodies Market is categorized into Murine, Humanized, Chimeric, and Human. The Human segment is the largest revenue contributor, accounting for more than half of the market share in 2021, and is anticipated to increase significantly throughout the forecast period. The integration of advanced technology such as phage or yeast display, as well as transgenic mice, for the generation of human monoclonal antibodies, is driving the segment. In addition, the use of advanced genetic engineering technology, an increase in the number of product approvals, and government support for infection control and management are the major factors driving the market's growth.
Humanized mAbs accounted for a considerable revenue share owing to their widespread use in the treatment of diseases such as cancer, autoimmune diseases, and inflammatory diseases. Furthermore, the use of advanced genetic engineering technologies in its manufacturing is a significant growth driver for this market.
Based on Indication, the Monoclonal Antibodies Market is categorized into Oncology, Inflammatory Diseases, Infectious Diseases, Autoimmune Diseases, and Others. The Oncology segment accounts for the largest share in the monoclonal antibodies market. The rise in the prevalence of cancer and the adoption of monoclonal antibodies in cancer treatment is driving the growth of the segment. Furthermore, the increase in the number of drug pipelines, rising patient awareness of cancer treatment processes, and demand for biosimilar monoclonal antibodies all contribute to the market's growth. These have shown to be the greatest cancer treatment option when compared to medications and chemotherapy owing to few side effects connected with their use. Therapeutic monoclonal antibodies (mAbs) have a wide range of applications in cancer treatment. mAbs are being utilized to treat a variety of cancers, including non-small cell lung cancer, breast cancer, brain tumors, ovarian cancer, colorectal cancer, melanoma, gastric cancer, Hodgkin's lymphoma, and others.
Based on End User, the Monoclonal Antibodies Market is categorized into Research Institutes, Hospitals, and Others. The Hospitals segment is anticipated to be worth roughly USD 77 billion in 2021 owing to the rising number of patient hospitalizations for a variety of chronic conditions. Patients' preferences have been influenced by the availability of modern medication therapy in institutions. Product demand in hospitals is likely to be driven by highly skilled experts providing specialized treatments such as cancer and autoimmune illnesses. The rising incidence of chronic illnesses is fueling treatment rates, and rising healthcare expenditure levels are factors that are likely to result in hospitals dominating the end-use segment during the forecast period.
Geographically, the North American Monoclonal Antibodies Market accounted for the largest revenue share of more than 48% in 2021 owing to the strong presence of key market players and an increasing number of product approvals. The demand for monoclonal antibodies in the regional market is likely to be fueled by increased product adoption for effective disease treatment. Furthermore, increased R&D spending by organizations and government backing for cancer research has enabled the development of innovative monoclonal antibody treatments. The availability of well-developed healthcare infrastructure has boosted the population's access to treatment, resulting in increasing product demand.
The Asia Pacific Monoclonal Antibodies Market is anticipated to grow at a rapid pace during the forecast period. Increasing initiatives and government spending for overall R&D of monoclonal antibody therapy, as well as a rise in the number of product approvals, delivers huge growth potential for key players operating in the monoclonal antibodies market. Furthermore, ongoing developments in monoclonal antibodies, the availability of modern healthcare systems, increasing patient knowledge of the therapeutic use of mAbs, and a large increase in demand for advanced healthcare facilities all contribute to the market's growth. Key manufacturers are increasingly focusing on growing their geographical presence in new markets.
Major Key Players in the Market
Some notable players operating in the global monoclonal antibodies market are
To strengthen their product portfolio and expand their market footprint, these market players are employing a variety of growth tactics. To acquire a competitive advantage, corporations are using competitive strategies such as product launches, mergers and acquisitions, expansion and diversification, and research collaborations.
Notable happenings in the Global Monoclonal Antibodies Market in the recent past:
The COVID-19 pandemic has had a favorable impact on the monoclonal antibody market for the development of COVID-19 monoclonal antibody therapy. The sudden increase in the number of individuals infected with COVID-19 prompted the development of viable treatments. The rapid production of a significant number of severe acute respiratory syndrome coronavirus neutralizing monoclonal antibodies has been aided by the urgent need for treatments available on a worldwide scale (mAbs). The Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for three monoclonal antibodies intended for outpatient treatment of symptomatic COVID-19 patients in response to the high transmission and significant fatality rates. The Centers for Medicare and Medicaid Services approved monoclonal antibody therapy with "bamlanivimab," "casirivimab/imdevimab," and "bamlanivimab/etesevimab" in November 2020 and April 2021, respectively. According to a report by the National Center for Biotechnology Information, the US government acquired 2.5 million monoclonal antibody therapies and distributed 1 million to states. Furthermore, according to the South Carolina Department of Health and Environmental Control report, the FDA has approved an mAB treatment for COVID-19 patients only for emergency use after it was found to be effective in reducing hospitalization and death by nearly 70% and shortening the treatment window by an average of four days. Furthermore, during the pandemic, a high number of active clinical trials to create novel pharmacological treatments, as well as a wide spectrum of pharmaceutical approvals for emergency use in COVID-19 treatment, fueled the market expansion
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
